Gilead Boosts U.S. Manufacturing Capacity to Advance Next-Generation Biologics

Gilead’s new Bay Area facility is supporting the American workforce while underscoring its commitment to strengthening U.S. biopharmaceutical leadership.

Gilead Sciences celebrated the groundbreaking of its new Pharmaceutical Development and Manufacturing Technical Development Center at the company’s headquarters in Foster City, California. Part of Gilead’s broader $32 billion investment in U.S. manufacturing and R&D through 2030, this new manufacturing hub will support the development of next-generation biologics and create more than 3,000 direct and indirect jobs.

Equipped with autonomous robots and digitally enabled systems, the state-of-the-art, 180,000-square-foot-facility will be one of the most AI-enabled centers in the industry. The center will accelerate technology transfer and support the advancement of next-generation biologics across Gilead’s pipeline.

The new site is part of a broader expansion at the company’s Foster City headquarters where Gilead is developing a new research facility to accelerate scientific discovery and house the company’s oncology and inflammation research. Designed with input from the researchers who will use it, the center will feature adaptable lap space, augmented reality, and digital twins.

Gilead’s commitment to domestic manufacturing and research is only made possible with the right policy environment. “We as an industry are leaning into those policies that help patients, but at the same time, we have to make sure those policies support and reward the innovation that has been the envy of the world,” said Daniel O’Day, Chairman & CEO, Gilead Sciences.

By continuing to expand its domestic manufacturing capacity and capabilities, Gilead is bringing transformative therapies to patients who need them most while fostering America’s leadership in biopharmaceutical innovation.